US2004110739A1PendingUtilityA1
Photochemotherapeutic method using 5-aminolevulinic acid and other precursors of endogenous porphyrins
Est. expiryJul 28, 2009(expired)· nominal 20-yr term from priority
A61K 41/0057A61K 31/555A61K 41/0071A61K 31/195A61K 41/0061Y02A50/30
62
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Methods of detecting and treating rapidly growing exogenous cells, such as Protista, or parasites, that preferentially accumulate a photoactivatable porphyrin in which 5-aminolevulinic acid or precursor thereof is administered to the patient, or contacted to the exogenous cells, in an amount sufficient to induce synthesis fluorescence and/or photosensitizing concentrations of a protoporphyrin IX in the exogenous cells, followed by exposure of the exogenous cells to light of photoactivating wavelengths.
Claims
exact text as granted — not AI-modified1 . A method for treating in a human patient a non-malignant skin lesion that preferentially accumulates a photoactivatable porphyrin, comprising administering to said human patient in need thereof an effective amount of a precursor of protoporphyrin IX thereby accumulating therapeutic levels of said protoporphyrin IX, and thereafter exposing said skin lesion to light capable of photoactivating said protoporphyrin IX.
2 . A method for detecting in a human patient a non-malignant skin lesion that preferentially accumulates a photoactivatable porphyrin, comprising administering to said human patient in need thereof an effective amount of a precursor of protoporphyrin IX thereby accumulating therapeutic levels of said protoporphyrin IX, and thereafter exposing said skin lesion to light capable of photoactivating said protoporphyrin IX.
3 . The method of any of claims 1 - 2 , wherein said precursor is administered topically.
4 . The method of any of claims 1 - 2 , wherein said precursor is 5-aminolevulinic acid.
5 . A method of treating a non-malignant skin lesion in a human patient in which protoporphyrin IX is produced from 5-aminolevulinic acid, comprising exposing said skin lesion in said human patient to a wavelength of light within the photoactivating spectrum of protoporphyrin Ix.
6 . The method of any of claims 1 - 2 or 6 , wherein said wavelength of light is 350-640 nm.
7 . The method of any of claims 1 - 2 or 6 , wherein said wavelength of light is 600-700 nm.
8 . The method of any of claims 1 - 2 or 6 , wherein said light is generated from an artificial light source.
9 . The method of any of claims 1 - 2 or 6 , wherein said light is only within the absorption spectrum of protoporphyrin IX.
10 . The method of any of claims 1 - 2 or 6 , wherein said photoactivating light is limited to the red and blue regions of the spectrum.
11 . A photosensitizing treatment method for treating non-malignant lesions of the skin in a human patient comprising
(a)administering an agent which is not a photosensitizer but induces the synthesis of protoporphyrin IX in vivo and then (b)exposing the lesions of the skin to a wavelength of light within the photoactivating spectrum of protoporphyrin IX.
12 . The method of claim 11 , wherein said agent induces synthesis of protoporphyrin IX in the heme biosynthetic pathway.
13 . The method of claim 11 , wherein said agent is a precursor of protoporphyrin IX.
14 . The method of claim 11 , wherein said wavelength of light is 350-640 nm.
15 . The method of claim 11 , wherein said wavelength of light is 600-700 nm.
16 . The method of claim 11 , wherein said agent is 5-amino levulinic acid.
17 . The method of claim 11 , wherein said agent is administered topically.
18 . The method of claim 11 , wherein said agent is administered systemically.
19 . The method of claim 11 , wherein said light is generated from an artificial light source.
20 . The method of claim 11 , wherein said light is only within the absorption spectrum of protoporphyrin IX.
21 . The method of claim 11 , wherein said photoactivating light is limited to the red and blue regions of the spectrum.Join the waitlist — get patent alerts
Track US2004110739A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.